Literature DB >> 289904

Combination chemotherapy for bone marrow relapse in childhood lymphoblastic leukaemia (ALL).

J M Chessells, M Cornbleet.   

Abstract

Thirty-four children with acute lymphoblastic leukaemia (ALL) in relapse or resistant to initial induction received combination chemotherapy with prednisolone, vincristine, l-asparaginase, and daunorubicin. L-asparaginase was given subcutaneously on alternate days for four weeks and was well tolerated. A complete remission was achieved in 96% of children in relapse and in five out of six children resistant to induction. Remission was achieved without hospitalisation in over 60% of patients. The median duration of subsequent remission was only 13 weeks, but six out of eight children receiving a second course of the drug combination achieved a further remission. We conclude that prolonged l-asparaginase therapy in combination with an anthracycline might well be used in initial or consolidation therapy for childhood ALL.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 289904     DOI: 10.1002/mpo.2950060413

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  4 in total

1.  VM26 therapy in children with drug-refractory lymphocytic leukemia.

Authors:  G Rivera; G V Dahl; S B Murphy; W P Bowman; R J Aur; T L Avery; J V Simone
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Infection during remission induction in childhood leukaemia.

Authors:  J M Chessells; A D Leiper
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

Review 3.  Childhood acute lymphoblastic leukaemia: a review.

Authors:  M L Willoughby
Journal:  J R Soc Med       Date:  1982-06       Impact factor: 18.000

4.  Long survival in childhood lymphoblastic leukaemia.

Authors:  J M Chessells; R M Hardisty; S Richards
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.